325 Results

People

  1. Lacouture
    Lacouture
  2. Kris
    Kris
  3. Hudis
    Hudis
  4. Motzer
    Motzer
  5. Saltz
    Saltz
  6. Seidman
    Seidman
  7. Heelan
    Heelan
  8. Kelsen
    Kelsen
  9. Ilson
    Ilson
  10. Norton
    Norton

Groups

  1. Department of Medicine (244)
  2. Solid Tumor Oncology Division (195)
  3. Survivorship Research (84)
  4. Gastrointestinal Oncology Service (57)
  5. Breast Medicine Service (46)
  6. Division of Subspecialty Medicine (45)
  7. Dermatology Service (41)
  8. Dermatology (41)
  9. Hematologic Malignancies, Division of (36)
  10. Surgery (34)
  1. "alopecia"
Formats
  1. Journal Article (301)
  2. Review (14)
  3. Conference Paper (5)
  4. Research Letter (3)
  5. Editorial (1)
  6. Guidelines (1)
Groups
  1. Department of Medicine (244)
  2. Solid Tumor Oncology Division (195)
  3. Survivorship Research (84)
  4. Gastrointestinal Oncology Service (57)
  5. Breast Medicine Service (46)
  6. Division of Subspecialty Medicine (45)

More Groups

People
  1. Mario Lacouture (38)
  2. Mark Kris (20)
  3. Clifford Hudis (15)
  4. Andrew Seidman (14)
  5. Leonard Saltz (14)
  6. Robert Motzer (14)

More People

Years
  1. 2025 (7)
  2. 2024 (20)
  3. 2023 (16)
  4. 2022 (11)
  5. 2021 (11)
  6. 2020 (14)

More Years

Publications
  1. Journal of Clinical Oncology (33)
  2. Cancer (14)
  3. Lancet Oncology (13)
  4. Clinical Cancer Research (12)
  5. Investigational New Drugs (11)
  6. Gynecologic Oncology (10)

More Publications

Publishers
  1. Elsevier Inc. (52)
  2. American Society of Clinical Oncology (35)
  3. Springer (31)
  4. Elsevier Science, Inc. (20)
  5. Wiley Blackwell (20)
  6. Oxford University Press (19)

More Publishers

Results (325)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Characterization and management of ERK inhibitor associated dermatologic adverse events: Analysis from a nonrandomized trial of ulixertinib for advanced cancers
    Journal Article

    Wu, J.; Liu, D.; Offin, M.; Lezcano, C.; Torrisi, J. M.; Brownstein, S.; Hyman, D. M.; Gounder, M. M.; Abida, W.; Drilon, A.; more...
    Investigational New Drugs (2021)

    Fulltext@MSK | Save
  • RETRACTED: Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): One cohort of a phase 2, multicentre, open-label, non-comparative study
    Journal Article

    Rugo, H. S.; Lerebours, F.; Ciruelos, E.; Drullinsky, P.; Ruiz-Borrego, M.; Neven, P.; Park, Y. H.; Prat, A.; Bachelot, T.; Juric, D.; more...
    Lancet Oncology (2021)

    Fulltext@MSK | Save
  • A phase I safety study of topical calcitriol (BPM31543) for the prevention of chemotherapy-induced alopecia
    Journal Article

    Lacouture, M. E.; Dion, H.; Ravipaty, S.; Jimenez, J. J.; Thapa, K.; Grund, E. M.; Benaim, E.; Tanna, N.; Luan, S.; DiTommaso, N.; more...
    Breast Cancer Research and Treatment (2021)

    Fulltext@MSK | Save
  • CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: An open-label, multicentre, phase 1b study
    Journal Article

    O'Hara, M. H.; O'Reilly, E. M.; Varadhachary, G.; Wolff, R. A.; Wainberg, Z. A.; Ko, A. H.; Fisher, G.; Rahma, O.; Lyman, J. P.; Cabanski, C. R.; more...
    Lancet Oncology (2021)

    Fulltext@MSK | Save
  • Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines
    Guidelines

    Lacouture, M. E.; Sibaud, V.; Gerber, P. A.; van den Hurk, C.; Fernández-Peñas, P.; Santini, D.; Jahn, F.; Jordan, K.; ESMO Guidelines Committe
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Integration of physician and nursing professional efforts to deliver supportive scalp cooling care to oncology patients at risk for alopecia
    Journal Article

    Peterson, L. L.; Lustberg, M.; Tolaney, S. M.; Ross, M.; Salehi, E.; Isakoff, S. J.
    Oncology and Therapy (2020)

    Fulltext@MSK | Save
  • Tazemetostat for patients with relapsed or refractory follicular lymphoma: An open-label, single-arm, multicentre, phase 2 trial
    Journal Article

    Morschhauser, F.; Tilly, H.; Chaidos, A.; McKay, P.; Phillips, T.; Assouline, S.; Batlevi, C. L.; Campbell, P.; Ribrag, V.; Damaj, G. L.; more...
    Lancet Oncology (2020)

    Fulltext@MSK | Save
  • Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features
    Review

    Ellis, S. R.; Vierra, A. T.; Millsop, J. W.; Lacouture, M. E.; Kiuru, M.
    Journal of the American Academy of Dermatology (2020)

    Fulltext@MSK | Save
  • Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): A double-blind, randomised, placebo-controlled, phase 3 trial
    Journal Article

    Blay, J. Y.; Serrano, C.; Heinrich, M. C.; Zalcberg, J.; Bauer, S.; Gelderblom, H.; Schöffski, P.; Jones, R. L.; Attia, S.; D'Amato, G.; more...
    Lancet Oncology (2020)

    Fulltext@MSK | Save
  • An international randomized phase III trial of pulse actinomycin-D versus multi-day methotrexate for the treatment of low risk gestational trophoblastic neoplasia; NRG/GOG 275
    Journal Article

    Schink, J. C.; Filiaci, V.; Huang, H. Q.; Tidy, J.; Winter, M.; Carter, J.; Anderson, N.; Moxley, K.; Yabuno, A.; Taylor, S. E.; more...
    Gynecologic Oncology (2020)

    Fulltext@MSK | Save